ACCPL

Accretion Pharmaceuticals Share Price

₹57.85 +0.7 (1.22%)

24 Oct, 2025 3:41 PM (IST)

SIP Trendup

Start SIP in ACCPL

Start SIP

Performance

  • Low
  • ₹56
  • High
  • ₹58
  • 52 Week Low
  • ₹54
  • 52 Week High
  • ₹83
  • Open Price₹58
  • Previous Close₹57
  • Volume8,400

Investment Returns

  • Over 1 Month -5.09%
  • Over 3 Month -7.44%
  • Over 6 Month -42.72%
  • Over 1 Year -42.72%
SIP Lightning

Smart Investing Starts Here Start SIP with Accretion Pharmaceuticals for Steady Growth!

Invest Now

Accretion Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 9.5
  • PEG Ratio
  • -
  • Market Cap Cr
  • 64
  • P/B Ratio
  • 3.9
  • Average True Range
  • 1.68
  • EPS
  • 6.11
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.35
  • RSI
  • 46.83
  • MFI
  • 40.67

Accretion Pharmaceuticals Financials

Accretion Pharmaceuticals Technicals

EMA & SMA

Current Price
₹57.85
+ 0.7 (1.22%)
pointer
  • stock-down_img
  • Bearish Moving Average 8
  • stock-up_img
  • Bullish Moving Average 5
  • 20 Day
  • ₹57.95
  • 50 Day
  • ₹60.26
  • 100 Day
  • ₹63.68
  • 200 Day
  • -

Resistance and Support

57.25 Pivot Speed
  • R3 60.25
  • R2 59.05
  • R1 58.45
  • S1 56.65
  • S2 55.45
  • S3 54.85

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Accretion Pharmaceuticals Limited manufactures high-quality pharmaceutical and nutraceutical products using advanced technology. With a state-of-the-art facility and over 200 professionals, it serves global markets by delivering affordable, effective healthcare solutions to improve lives and build healthier communities.

Accretion Pharmaceuticals Ltd has an operating revenue of Rs. 142.72 Cr. on a trailing 12-month basis. An annual revenue growth of 69% is outstanding, Pre-tax margin of 17% is great, ROE of 44% is exceptional. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 15 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 93 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Accretion Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-06-10 Audited Results & Others To consider Other business matters.

Accretion Pharmaceuticals F&O

Accretion Pharmaceuticals Shareholding Pattern

73.52%
1.16%
22.86%
2.46%

About Accretion Pharmaceuticals

  • NSE Symbol
  • ACCPL
  • BSE Symbol
  • Managing Director
  • Mr. Vivek Ashok Kumar Patel
  • ISIN
  • INE0T8T01010

Similar Stocks to Accretion Pharmaceuticals

Accretion Pharmaceuticals FAQs

Accretion Pharmaceuticals share price is ₹57 As on 27 October, 2025 | 01:15

The Market Cap of Accretion Pharmaceuticals is ₹64.3 Cr As on 27 October, 2025 | 01:15

The P/E ratio of Accretion Pharmaceuticals is 9.5 As on 27 October, 2025 | 01:15

The PB ratio of Accretion Pharmaceuticals is 3.9 As on 27 October, 2025 | 01:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23